Table 2.

Change in laboratory values from baseline to end of treatment according to treatment group (efficacy population)

	PA21					Sevelamer-HCl (n=24)
	1.25 g/d (n=26)	5.0 g/d (n=26)	7.5 g/d (n=25)	10.0 g/d (n=25)	12.5 g/d (n=24)
Serum phosphorus (mg/dl)
Baseline	6.82±1.64	6.61±1.08	6.85±1.15	6.77±1.75	6.47±1.19	6.94±1.61
End of treatment	6.69±2.05	5.53±1.94	5.60±1.18	4.77±1.92	4.78±1.67	5.88±1.47
Change	−0.13±2.01	−1.08±2.12	−1.25±1.21	−2.00±1.71	−1.69±1.81	−1.06±1.35
P valuea (LOCF applied)	0.75	0.02	<0.001	<0.001	<0.001	<0.001
95% CI (LOCF applied)	−0.94, 0.68	−1.93, -0.20	−1.75, -0.70	−2.70, -1.20	−2.46, -0.90	−1.62, -0.40
Serum calcium (mg/dl)
Baseline	8.53±0.68	8.55±0.71	8.63±0.43	8.39±0.84	8.54±0.56	8.57±0.57
End of treatment	8.30±1.22	8.67±0.92	8.79±0.59	8.49±1.23	8.39±1.08	8.85±0.57
Change	−0.23±1.22	0.12±0.80	0.16±0.60	0.10±0.96	−0.15±0.88	0.25±0.57
P valuea	0.35	0.46	0.19	0.62	0.40	0.04
95% CI	−0.72, 0.26	−0.20, 0.44	−0.09, 0.41	−0.30, 0.49	−0.53, 0.22	0.01, 0.50
Ca×P (mg2/dl2)
Baseline	58.13±14.23	56.77±11.38	59.09±10.29	57.31±17.11	54.98±9.29	59.28±13.38
End of treatment	55.74±18.70	48.27±17.22	48.02±9.90	40.21±18.23	39.99±15.25	50.23±12.41
Change	−2.39±22.95	−8.50±19.20	−11.07±10.36	−17.10±16.35	−14.99±15.97	−9.71±12.91
P valuea	0.60	0.03	<0.001	<0.001	<0.001	0.002
95% CI	−11.66, 6.88	−16.26, -0.70	−15.35, -6.80	−23.85, -10.30	−21.73, -8.20	−15.30, -4.10
Serum iPTH (ng/L)
Baseline	238±189	228±171	272±148	245±139	222±152	262±144
End of treatment	246±191	217±165	272±197	225±156	162±93	225±137
Change	7±69	−11±128	0±142	−20±85	−61±106	−39±80
P valuea	0.59	0.67	1.00	0.25	<0.01	<0.03
95% CI	−20, 35	−63, 41	−59, 59	−55, 15	−105, -16	−73, -4

Values are shown as mean ± SD. LOCF, last observation carried forward; Ca×P, calcium × phosphorus; CI, confidence interval; iPTH, intact parathyroid hormone.

^aTwo-sided single sample t test.